Trial Profile

Study of incidence of active tuberculosis in patients with lung cancer treated with immune checkpoint inhibitors

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 11 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions

Most Recent Events

01 Nov 2022 Results evaluating the interferon-gamma release assay (IGRA) conversion rate and active tuberculosis incidence during immunotherapy to elucidate the incidence of tuberculosis reactivation after ICI therapy induction,published in the Cancer Immunology Immunotherapy
26 Jun 2021 New trial record
19 May 2021 Results presented at the 117th International Conference of the American Thoracic Society.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com